跳到正文
原文
NEJM· @NEJM · X·· 2026-10-17精选AI 评分58
AI 导读

NEJM 以 Quick Take 视频形式解读了 3 期 GIMEMA ALL2820 试验的研究结果,该试验评估一线靶向联合免疫治疗策略能否成为 Ph 阳性 ALL 中 TKI 联合化疗的有效替代方案。此前这一问题的答案尚不明确。

正文

Whether a frontline targeted-plus-immunotherapy strategy would be an effective alternative to a TK inhibitor plus chemotherapy in Ph-positive ALL has been unclear. Research findings from the phase 3 GIMEMA ALL2820 trial are summarized in a new Quick Take video. https://nej.md/4s6djRa

来源:NEJM · x.com